Results 131 to 140 of about 14,484 (178)
Some of the next articles are maybe not open access.
Drugs & Aging, 2009
The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the long-term impact of diseases on functional status and on costs are greater in older people than in any other age group.
Bustacchini, S. +6 more
openaire +3 more sources
The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the long-term impact of diseases on functional status and on costs are greater in older people than in any other age group.
Bustacchini, S. +6 more
openaire +3 more sources
Pharmacoeconomics of darunavir
Expert Review of Pharmacoeconomics & Outcomes Research, 2011Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008.
Dwight S, Fullerton +3 more
openaire +2 more sources
Expert Review of Pharmacoeconomics & Outcomes Research, 2002
Healthcare costs in the USA continue to rise faster than the consumer price index. Nothing demonstrates this more vividly than the double-digit increases posted for the cost of the drug treatment of the oncology patient. A factor that will compound this cost is the expansion in the oncology patient population that will occur as the population ages ...
Rebecca B, Arbuckle +2 more
openaire +2 more sources
Healthcare costs in the USA continue to rise faster than the consumer price index. Nothing demonstrates this more vividly than the double-digit increases posted for the cost of the drug treatment of the oncology patient. A factor that will compound this cost is the expansion in the oncology patient population that will occur as the population ages ...
Rebecca B, Arbuckle +2 more
openaire +2 more sources
Pharmacoeconomics of linezolid
Expert Opinion on Pharmacotherapy, 2008New antibiotics efficacious in infections caused by resistant Gram-positive microorganisms and with acceptable costs for national health systems per unit of effectiveness are needed.This paper aimed to summarize all available evidence regarding the pharmacoeconomics of linezolid.A systematic review of pharmacoeconomic analyses through a non-restricted ...
Santiago, Grau, Carlos, Rubio-Terrés
openaire +2 more sources
Pharmacoeconomics of etravirine
Expert Review of Pharmacoeconomics & Outcomes Research, 2010HIV infection, particularly multidrug-resistant HIV, continues to be a major societal and economic challenge worldwide. Etravirine, a new (US FDA approved in 2008) non-nucleoside reverse transcriptase inhibitor, has been shown to be very effective in treating patients who have failed prior antiretroviral therapy.
D S, Fullerton +5 more
openaire +2 more sources
Pharmacoeconomics of voriconazole
Expert Opinion on Pharmacotherapy, 2010The recent increase in the use of antineoplastic and immune suppressive agents and the use of broad-spectrum antibiotics, prosthetic interventions, organ transplants and more aggressive surgery have been related to a greater prevalence of invasive fungal infections (IFI).
Carlos, Rubio-Terrés, Santiago, Grau
openaire +2 more sources
Pharmacoeconomics of Immunisation
PharmacoEconomics, 1993The effects of immunisation programmes that have existed for several decades in developed countries are demonstrated by the decrease and even eradication of smallpox, poliomyelitis, measles, mumps and hepatitis B. Cost, health policy and spontaneous evolution in the incidence of communicable diseases have a decisive influence on the use of a vaccine.
R, van den Oever +9 more
openaire +2 more sources
Update on pharmacoeconomics in transplantation
Progress in Transplantation, 2007Purpose To provide current information on pharmacoeconomic outcomes in transplantation for the past 6 years. Methods An extensive literature search was undertaken using PubMed and other authenticated Internet sources. Key words used to
Teresa M, Cavanaugh, Jill E, Martin
openaire +2 more sources
Pharmacoeconomics of pneumonia
The American Journal of Surgery, 2000Because diagnosis and treatment are so intimately linked, the pharmacoeconomics of treatment of ventilator-associated pneumonia (VAP) is impossible to discuss without discussing the cost-effectiveness of VAP diagnosis. The cost of VAP treatment is more complex than simply drug acquisition and administration costs.
openaire +2 more sources
Pharmacoeconomic considerations
American Journal of Health-System Pharmacy, 2003Pharmacoeconomic analyses can be readily applied to the study of venous thromboembolism (VTE) in the orthopedic postsurgical setting. The cost of VTE to the health care system and a cost-effectiveness trial that utilized a factor Xa inhibitor for VTE prophylaxis are discussed.
openaire +2 more sources